Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)
Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%
Castle Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Castle Biosciences's operating margin for the twelve months ending Sep 30, 2026 was -7.4%. For fiscal 2025 it was -12.4%, against 2.6% the year before. The highest annual figure on record is 14.1% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -12.4% | −15.0 |
| FY2024 | Dec 31, 2024 | 2.6% | +33.5 |
| FY2023 | Dec 31, 2023 | -30.9% | +22.2 |
| FY2022 | Dec 31, 2022 | -53.2% | −10.6 |
| FY2021 | Dec 31, 2021 | -42.6% | −32.2 |
| FY2020 | Dec 31, 2020 | -10.4% | −24.6 |
| FY2019 | Dec 31, 2019 | 14.1% | +31.0 |
| FY2018 | Dec 31, 2018 | -16.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -2.7% | +5.5 |
| Q2 FY2026 | Jun 30, 2026 | -3.0% | +2.0 |
| Q1 FY2026 | Mar 31, 2026 | -22.0% | +9.7 |
| Q4 FY2025 | Dec 31, 2025 | -4.4% | −9.1 |
| Q3 FY2025 | Sep 30, 2025 | -8.2% | −14.1 |
| Q2 FY2025 | Jun 30, 2025 | -4.9% | −10.7 |
| Q1 FY2025 | Mar 31, 2025 | -31.7% | −24.2 |
| Q4 FY2024 | Dec 31, 2024 | 4.7% | +13.2 |
| Q3 FY2024 | Sep 30, 2024 | 5.9% | +21.6 |
| Q2 FY2024 | Jun 30, 2024 | 5.8% | +48.0 |
| Q1 FY2024 | Mar 31, 2024 | -7.5% | +67.5 |
| Q4 FY2023 | Dec 31, 2023 | -8.6% | +51.0 |
| Q3 FY2023 | Sep 30, 2023 | -15.7% | +42.5 |
| Q2 FY2023 | Jun 30, 2023 | -42.2% | −30.8 |
| Q1 FY2023 | Mar 31, 2023 | -75.0% | +16.3 |
| Q4 FY2022 | Dec 31, 2022 | -59.6% | +1.0 |
| Q3 FY2022 | Sep 30, 2022 | -58.2% | −7.9 |
| Q2 FY2022 | Jun 30, 2022 | -11.4% | +27.3 |
| Q1 FY2022 | Mar 31, 2022 | -91.3% | −72.5 |
| Q4 FY2021 | Dec 31, 2021 | -60.6% | −43.1 |
| Q3 FY2021 | Sep 30, 2021 | -50.3% | −24.7 |
| Q2 FY2021 | Jun 30, 2021 | -38.7% | −33.6 |
| Q1 FY2021 | Mar 31, 2021 | -18.8% | −24.7 |
| Q4 FY2020 | Dec 31, 2020 | -17.5% | −32.3 |
| Q3 FY2020 | Sep 30, 2020 | -25.6% | −55.6 |
| Q2 FY2020 | Jun 30, 2020 | -5.1% | −10.7 |
| Q1 FY2020 | Mar 31, 2020 | 5.9% | +9.6 |
| Q4 FY2019 | Dec 31, 2019 | 14.8% | −26.9 |
| Q3 FY2019 | Sep 30, 2019 | 30.0% | +106.8 |
| Q2 FY2019 | Jun 30, 2019 | 5.7% | +72.7 |
| Q1 FY2019 | Mar 31, 2019 | -3.7% | – |
| Q4 FY2018 | Dec 31, 2018 | 41.7% | – |
| Q3 FY2018 | Sep 30, 2018 | -76.8% | – |
| Q2 FY2018 | Jun 30, 2018 | -67.0% | – |
See a number that looks wrong?